Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ramipril And Loperamide Shoot Up In Early 2021

Pricewatch UK – January 2021

Executive Summary

Both ramipril and loperamide saw average UK trade prices that more than doubled in January 2021.

You may also be interested in...



UK Price Movements Muted In A Quiet December

As the UK continued to see a mixture of national lockdown measures and regional restrictions to mitigate the coronavirus pandemic, as well as preparing for the end of its transition period with the EU and the end-of-year holiday period, price changes were unusually muted in December.

Hyloris Pushes Into South America With Maxigesic IV

Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.

Australia Extends Biosimilar Education Efforts

Australia’s government has agreed to extend a successful biosimilar education initiative led by the local GBMA industry association.

Topics

UsernamePublicRestriction

Register

GB150654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel